Zydus Lifesciences (ZYDUSLIF) has shown resilience in the face of recent stock price corrections and rising competition in the U.S. generics market.

Prabhudas Lilladher has issued an Accumulate rating on Aurobindo Pharma Ltd. (ARBP), setting a target price of Rs 1,475.

Prabhudas Lilladher has reaffirmed its Buy rating on Fortis Healthcare (FORH), setting a revised target price of Rs 710, indicating a potential upside from the current market price of Rs 621.

Prabhudas Lilladher has reaffirmed its Buy rating for Lupin (LPC), raising the target price to Rs 2,420. This revision underscores confidence in Lupin’s strong performance in the U.S.

KRChoksey Research has reaffirmed its "BUY" call on Granules India Ltd, targeting a price of Rs 700, which presents an upside potential of 22.4% from its current market price (CMP) of Rs 572.

KRChoksey has recommended an "ACCUMULATE" rating for Cipla Ltd. with a target price of Rs 1,680, indicating a potential upside of 6.0% from the current market price of Rs 1,585.